Afya (NASDAQ:AFYA – Free Report) had its price target trimmed by JPMorgan Chase & Co. from $25.00 to $20.50 in a research report sent to investors on Friday,Benzinga reports. The firm currently has a neutral rating on the stock.
Separately, The Goldman Sachs Group began coverage on shares of Afya in a report on Tuesday, December 3rd. They issued a “sell” rating and a $16.00 target price on the stock. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $19.60.
Get Our Latest Analysis on AFYA
Afya Stock Up 0.6 %
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Lifestyle Asset Management Inc. increased its position in Afya by 5.5% during the 4th quarter. Lifestyle Asset Management Inc. now owns 17,682 shares of the company’s stock worth $281,000 after purchasing an additional 929 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new stake in Afya during the 3rd quarter worth approximately $34,000. Quarry LP acquired a new stake in Afya during the 3rd quarter worth approximately $75,000. Quantbot Technologies LP increased its position in Afya by 73.8% during the 3rd quarter. Quantbot Technologies LP now owns 13,268 shares of the company’s stock worth $226,000 after purchasing an additional 5,636 shares in the last quarter. Finally, Centiva Capital LP acquired a new stake in Afya during the 3rd quarter worth approximately $213,000. 88.02% of the stock is currently owned by hedge funds and other institutional investors.
Afya Company Profile
Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company operates through three segments: Undergrad, Continuing Education, and Digital Services. It offers educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.
See Also
- Five stocks we like better than Afya
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Earn High Dividends With 2 Top REITs Set to Perform in 2025
- What is the Shanghai Stock Exchange Composite Index?
- Oilfield Leader SLB: An AI Name You Need to Know
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Top ETFs That Beat the Market in 2024 and Could Do It Again
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.